DNA Therapeutics S.A. is a privately-owned, emerging biopharmaceutical company dedicated to the development of life-saving therapeutics to combat treatment-resistant cancers. It is founded on a uniquely positioned paradigm-shift technology, siDNA, which deals with DNA repair pathways as a global target, instead of targeting a key gene/protein whatever its biological importance and clinical relevance. This is an innovative approach in conjunction with radiotherapy and chemotherapy for cost effective and efficient therapeutics focused on highly unmet medical needs.

- Vision

Progression of cancer is associated with the deregulation of many genes involved in multiple pathways responsible for controlling cell growth and differentiation including cell cycle, programmed cell death, intra- and inter-cellular communication, and DNA repair processes. Discovery and development of new drugs at DNA Therapeutics are based on the knowledge of DNA damage sensing, signaling and repair. DNA Therapeutics opens an innovative approach, to improve the efficacy of chemotherapeutic drugs and radiotherapy, and thus address unmet medical needs in cancer treatment.

- Mission

Developing the cutting-edge technologies and innovative medicines that will significantly improve the treatment of cancer by inhibiting DNA repair related processes, overcoming cancer cell resistance to conventional therapy and in this way achieving better clinical outcomes.

- Strategy

DNA Therapeutics aims to strengthen and exploit the utmost from siDNA technology, a pathway targeting and mechanism-oriented approach, and to add progressively other anticancer weapons to its armamentarium in order to enrich its product pipeline for addressing unmet medical needs in cancer. It will focus on business-driven drug development for established strategic partners who will be in charge of late stage development, marketing and commercialization.

- Ambition

Entering the biopharmaceutical arena thanks to a proprietary cutting edged siDNA technology and innovative medicines with strong translational research support from the renowned public research institutions: bringing this paradigm-shift approach to success by validating the siDNA concept in the clinic and by leveraging its financial consequences; becoming a  successful VIPCo (Virtually Integrated Pharmaceutical Company) with a well balanced and sustained pipeline; Playing a key role in the advancement of therapies against cancer and at a future stage other biologically related diseases.